Prevention of swine erysipelas (SE) is based on vaccination, which relies on the protective role of the specific antibodies against Erysipelothrix rhusiopathiae. Despite the proven efficacy of existing vaccines, inadequate vaccination protocols may lead to the emergence of SE outbreaks, as recently reported in Japan and Australia. Therefore, serological monitoring of SE is essential in disease control. The aim of this study was to compare two commercial ELISA kits in terms of their competence to assess immunization of SE vaccinated and naturally infected pigs.
Experimental and field evaluation of the performance of two ELISA methods to detect seroconversion against swine erysipelas in pigs
Related products
The first intradermal needle-free vaccine against Mycoplasma hyopneumoniae and PCV2, all in one, in suspension for injection
Live vaccine against porcine reproductive and respiratory syndrome (PRRS), in injectable freeze-dried tablet
Purified recombinant verotoxin 2e against edema disease, in suspension for injection
Inactivated vaccine, against progressive and non progressive swine atrophic rhinitis, in injectable suspension.
Inactivated vaccine against neonatal colibacillosis and Clostridium infections in swine, in injectable suspension
Inactivated vaccine against Clostridioides difficile and Clostridium perfringens type A infections in swine, in injectable suspension.
Inactivated vaccine against porcine parvovirus and swine erysipelas, in injectable suspension
Inactivated vaccine against swine erysipelas, parvovirosis and leptospirosis, in injectable suspension
Live vaccine against Aujeszky’s disease gE negative strain, in injectable freeze-dried tablet
Inactivated vaccine against swine erysipelas, in injectable suspension
Inactivated porcine against porcine parvovirus, in injectable suspension
Inactivated vaccine against enzootic pneumonia, in injectable suspension